These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 29795041)

  • 101. EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF
    Fu Y; Rathod D; Abo-Ali EM; Dukhande VV; Patel K
    Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31581483
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Quaternized chitosan promotes the antiproliferative effect of vemurafenib in melanoma cells by increasing cell permeability.
    Li M; Yang Y
    Onco Targets Ther; 2018; 11():8293-8299. PubMed ID: 30538498
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives.
    Chacón M; Pfluger Y; Angel M; Waisberg F; Enrico D
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32825562
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Indolium 1 Exerts Activity against Vemurafenib-Resistant Melanoma In Vivo.
    Radi R; Huang C; Elsey J; Jung YH; Corces VG; Arbiser JL
    Antioxidants (Basel); 2022 Apr; 11(5):. PubMed ID: 35624662
    [TBL] [Abstract][Full Text] [Related]  

  • 105. A Rare Case of Non-Small Cell Lung Cancer with BRAF V600E Gene: Case Report and Literature Review.
    Patel D; Mubarik A; Patel S; Vaziri A; Muddassir S
    Cureus; 2020 Feb; 12(2):e7055. PubMed ID: 32219049
    [TBL] [Abstract][Full Text] [Related]  

  • 106. T-Type Calcium Channels: A Potential Novel Target in Melanoma.
    Barceló C; Sisó P; Maiques O; de la Rosa I; Martí RM; Macià A
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32046241
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Functional Genomic Screening Independently Identifies CUL3 as a Mediator of Vemurafenib Resistance via Src-Rac1 Signaling Axis.
    Vanneste M; Feddersen CR; Varzavand A; Zhu EY; Foley T; Zhao L; Holt KH; Milhem M; Piper R; Stipp CS; Dupuy AJ; Henry MD
    Front Oncol; 2020; 10():442. PubMed ID: 32346533
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Response of metastatic glioma to vemurafenib.
    Leaver KE; Zhang N; Ziskin JL; Vogel H; Recht L; Thomas RP
    Neurooncol Pract; 2016 Dec; 3(4):268-271. PubMed ID: 31386052
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Drug targets and predictive biomarkers in the management of metastatic melanoma.
    Thumar J; Giesen E; Kluger HM
    Pharmgenomics Pers Med; 2012; 5():139-48. PubMed ID: 23226069
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Natural Killer cell control of
    de Andrade LF; Ngiow SF; Martinet L; Smyth MJ
    Oncoimmunology; 2015 Apr; 4(4):e998119. PubMed ID: 26137412
    [TBL] [Abstract][Full Text] [Related]  

  • 111. RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma.
    Reuben A; Amaria RN; Cooper ZA; Wargo JA
    J Pigment Disord; 2014 Nov; 1(5):. PubMed ID: 29250602
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Multidisciplinary Therapy Managed Recurrent Glioblastoma in a BRAF-V600E Mutant Pregnant Female: A Case Report and Review of the Literature.
    Qin C; Long W; Zhang C; Xie Y; Wu C; Li Y; Xiao Q; Ji N; Liu Q
    Front Oncol; 2020; 10():522816. PubMed ID: 33117675
    [No Abstract]   [Full Text] [Related]  

  • 113. ERBB3 is required for metastasis formation of melanoma cells.
    Tiwary S; Preziosi M; Rothberg PG; Zeitouni N; Corson N; Xu L
    Oncogenesis; 2014 Jul; 3(7):e110. PubMed ID: 25000258
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Oral malignant melanoma: A report of two cases with BRAF molecular analysis.
    Soma PF; Pettinato A; Agnone AM; Donia C; Improta G; Fraggetta F
    Oncol Lett; 2014 Sep; 8(3):1283-1286. PubMed ID: 25120707
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring.
    Klinac D; Gray ES; Millward M; Ziman M
    Front Oncol; 2013; 3():54. PubMed ID: 23515890
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Melanoma: oncogenic drivers and the immune system.
    Karachaliou N; Pilotto S; Teixidó C; Viteri S; González-Cao M; Riso A; Morales-Espinosa D; Molina MA; Chaib I; Santarpia M; Richardet E; Bria E; Rosell R
    Ann Transl Med; 2015 Oct; 3(18):265. PubMed ID: 26605311
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Tumor talk: understanding the conversation between the tumor and its microenvironment.
    Whipple CA
    Cancer Cell Microenviron; 2015 Apr; 2(2):e773. PubMed ID: 26023680
    [TBL] [Abstract][Full Text] [Related]  

  • 118. New treatment approaches in melanoma: current research and clinical prospects.
    Rughani MG; Gupta A; Middleton MR
    Ther Adv Med Oncol; 2013 Jan; 5(1):73-80. PubMed ID: 23323148
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Chemotherapy Resistance Mechanisms in Advanced Skin Cancer.
    Kalal BS; Upadhya D; Pai VR
    Oncol Rev; 2017 Mar; 11(1):326. PubMed ID: 28382191
    [TBL] [Abstract][Full Text] [Related]  

  • 120. A Blue Light-Inducible CRISPR-Cas9 System for Inhibiting Progression of Melanoma Cells.
    Wu X; Huang H; Yu B; Zhang J
    Front Mol Biosci; 2020; 7():606593. PubMed ID: 33330635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.